HEADER TRANSFERASE 06-JUN-23 8JNY TITLE MUTATED HUMAN ADP-RIBOSYLTRANSFERASE 2 (PARP2) CATALYTIC DOMAIN BOUND TITLE 2 TO A PYRAZOLOPYRIMIDINE CARBOXAMIDE INHIBITOR COMPND MOL_ID: 1; COMPND 2 MOLECULE: POLY [ADP-RIBOSE] POLYMERASE 2; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: PARP-2,HPARP-2,ADP-RIBOSYLTRANSFERASE DIPHTHERIA TOXIN-LIKE COMPND 5 2,ARTD2,DNA ADP-RIBOSYLTRANSFERASE PARP2,NAD(+) ADP- COMPND 6 RIBOSYLTRANSFERASE 2,ADPRT-2,POLY[ADP-RIBOSE] SYNTHASE 2,PADPRT-2, COMPND 7 PROTEIN POLY-ADP-RIBOSYLTRANSFERASE PARP2; COMPND 8 EC: 2.4.2.30,2.4.2.-; COMPND 9 ENGINEERED: YES; COMPND 10 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: PARP2, ADPRT2, ADPRTL2; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS DNA ADP-RIBOSYLTRANSFERASE 2, PARP2, PARP INHIBITOR, TRANSFERASE EXPDTA X-RAY DIFFRACTION AUTHOR X.Y.WANG,C.Y.WANG,J.ZHOU,B.L.XU REVDAT 1 12-JUN-24 8JNY 0 JRNL AUTH X.Y.WANG,C.Y.WANG,J.ZHOU,B.L.XU JRNL TITL MUTATED HUMAN ADP-RIBOSYLTRANSFERASE 2 (PARP2) CATALYTIC JRNL TITL 2 DOMAIN BOUND TO A PYRAZOLOPYRIMIDINE CARBOXAMIDE INHIBITOR JRNL REF TO BE PUBLISHED JRNL REFN REMARK 2 REMARK 2 RESOLUTION. 3.20 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX 1.20.1_4487 REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : GEOSTD + MONOMER LIBRARY + CDL V1.2 REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 3.20 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 42.38 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.360 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.8 REMARK 3 NUMBER OF REFLECTIONS : 11153 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.222 REMARK 3 R VALUE (WORKING SET) : 0.220 REMARK 3 FREE R VALUE : 0.268 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.690 REMARK 3 FREE R VALUE TEST SET COUNT : 523 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 42.3800 - 5.0800 1.00 2685 125 0.1900 0.2356 REMARK 3 2 5.0800 - 4.0300 1.00 2659 120 0.2069 0.2386 REMARK 3 3 4.0300 - 3.5200 1.00 2639 156 0.2436 0.3088 REMARK 3 4 3.5200 - 3.2000 1.00 2647 122 0.2783 0.3330 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : FLAT BULK SOLVENT MODEL REMARK 3 SOLVENT RADIUS : 1.10 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : NULL REMARK 3 B_SOL : NULL REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.345 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 26.160 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 65.48 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 58.46 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.003 5715 REMARK 3 ANGLE : 0.616 7709 REMARK 3 CHIRALITY : 0.039 843 REMARK 3 PLANARITY : 0.005 993 REMARK 3 DIHEDRAL : 19.039 2166 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 8JNY COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBC ON 15-JUN-23. REMARK 100 THE DEPOSITION ID IS D_1300038298. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 24-AUG-22 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 8.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SSRF REMARK 200 BEAMLINE : BL02U1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.979183 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS EIGER X 16M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : NULL REMARK 200 DATA SCALING SOFTWARE : AIMLESS REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 11162 REMARK 200 RESOLUTION RANGE HIGH (A) : 3.200 REMARK 200 RESOLUTION RANGE LOW (A) : 42.380 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.8 REMARK 200 DATA REDUNDANCY : 6.000 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 11.0800 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 3.20 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 3.32 REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: MOLREP REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 42.18 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.13 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 25% PEG-3350, 0.1 M TRIS-HCL PH 8.5, REMARK 280 VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 291K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 43.77350 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 551 REMARK 465 GLY B 295 REMARK 465 GLY B 314 REMARK 465 GLY B 493 REMARK 465 LYS B 512 REMARK 465 GLY B 539 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 PRO A 230 -106.45 -91.09 REMARK 500 LYS A 269 51.72 -108.65 REMARK 500 ARG A 351 -131.17 33.60 REMARK 500 GLN A 352 74.94 -162.64 REMARK 500 HIS A 394 55.90 -107.76 REMARK 500 ARG A 417 84.88 -65.65 REMARK 500 LYS A 459 96.20 -68.56 REMARK 500 LYS A 504 31.15 -77.80 REMARK 500 GLN A 510 72.81 43.15 REMARK 500 LEU A 538 -156.24 -80.41 REMARK 500 ARG A 570 -55.90 -132.72 REMARK 500 PRO B 230 -156.26 -115.95 REMARK 500 LYS B 263 -74.84 -87.29 REMARK 500 LYS B 269 77.86 -103.23 REMARK 500 HIS B 311 -160.94 -104.55 REMARK 500 ASP B 312 75.75 -165.46 REMARK 500 GLU B 350 120.75 68.01 REMARK 500 GLN B 352 -152.24 62.23 REMARK 500 LEU B 354 77.93 -171.78 REMARK 500 GLU B 355 177.53 64.79 REMARK 500 PRO B 357 -44.93 -28.42 REMARK 500 THR B 393 -88.95 -65.51 REMARK 500 HIS B 394 80.91 -55.43 REMARK 500 ASP B 410 80.45 -59.24 REMARK 500 ARG B 417 79.75 -109.78 REMARK 500 ARG B 478 -45.39 -27.90 REMARK 500 LYS B 480 71.05 -101.54 REMARK 500 ASN B 496 72.15 -151.12 REMARK 500 SER B 525 2.59 -64.37 REMARK 500 ALA B 541 65.57 -102.04 REMARK 500 ASP B 550 -33.99 -154.46 REMARK 500 ARG B 570 -53.87 -137.89 REMARK 500 PHE B 579 -150.86 -88.11 REMARK 500 REMARK 500 REMARK: NULL DBREF 8JNY A 230 581 UNP Q9UGN5 PARP2_HUMAN 230 581 DBREF 8JNY B 230 581 UNP Q9UGN5 PARP2_HUMAN 230 581 SEQADV 8JNY GLY A 229 UNP Q9UGN5 EXPRESSION TAG SEQADV 8JNY SER A 349 UNP Q9UGN5 THR 349 ENGINEERED MUTATION SEQADV 8JNY ARG A 351 UNP Q9UGN5 LEU 351 ENGINEERED MUTATION SEQADV 8JNY GLY A 353 UNP Q9UGN5 SER 353 ENGINEERED MUTATION SEQADV 8JNY LEU A 354 UNP Q9UGN5 PRO 354 ENGINEERED MUTATION SEQADV 8JNY GLY B 229 UNP Q9UGN5 EXPRESSION TAG SEQADV 8JNY SER B 349 UNP Q9UGN5 THR 349 ENGINEERED MUTATION SEQADV 8JNY ARG B 351 UNP Q9UGN5 LEU 351 ENGINEERED MUTATION SEQADV 8JNY GLY B 353 UNP Q9UGN5 SER 353 ENGINEERED MUTATION SEQADV 8JNY LEU B 354 UNP Q9UGN5 PRO 354 ENGINEERED MUTATION SEQRES 1 A 353 GLY PRO GLU SER GLN LEU ASP LEU ARG VAL GLN GLU LEU SEQRES 2 A 353 ILE LYS LEU ILE CYS ASN VAL GLN ALA MET GLU GLU MET SEQRES 3 A 353 MET MET GLU MET LYS TYR ASN THR LYS LYS ALA PRO LEU SEQRES 4 A 353 GLY LYS LEU THR VAL ALA GLN ILE LYS ALA GLY TYR GLN SEQRES 5 A 353 SER LEU LYS LYS ILE GLU ASP CYS ILE ARG ALA GLY GLN SEQRES 6 A 353 HIS GLY ARG ALA LEU MET GLU ALA CYS ASN GLU PHE TYR SEQRES 7 A 353 THR ARG ILE PRO HIS ASP PHE GLY LEU ARG THR PRO PRO SEQRES 8 A 353 LEU ILE ARG THR GLN LYS GLU LEU SER GLU LYS ILE GLN SEQRES 9 A 353 LEU LEU GLU ALA LEU GLY ASP ILE GLU ILE ALA ILE LYS SEQRES 10 A 353 LEU VAL LYS SER GLU ARG GLN GLY LEU GLU HIS PRO LEU SEQRES 11 A 353 ASP GLN HIS TYR ARG ASN LEU HIS CYS ALA LEU ARG PRO SEQRES 12 A 353 LEU ASP HIS GLU SER TYR GLU PHE LYS VAL ILE SER GLN SEQRES 13 A 353 TYR LEU GLN SER THR HIS ALA PRO THR HIS SER ASP TYR SEQRES 14 A 353 THR MET THR LEU LEU ASP LEU PHE GLU VAL GLU LYS ASP SEQRES 15 A 353 GLY GLU LYS GLU ALA PHE ARG GLU ASP LEU HIS ASN ARG SEQRES 16 A 353 MET LEU LEU TRP HIS GLY SER ARG MET SER ASN TRP VAL SEQRES 17 A 353 GLY ILE LEU SER HIS GLY LEU ARG ILE ALA PRO PRO GLU SEQRES 18 A 353 ALA PRO ILE THR GLY TYR MET PHE GLY LYS GLY ILE TYR SEQRES 19 A 353 PHE ALA ASP MET SER SER LYS SER ALA ASN TYR CYS PHE SEQRES 20 A 353 ALA SER ARG LEU LYS ASN THR GLY LEU LEU LEU LEU SER SEQRES 21 A 353 GLU VAL ALA LEU GLY GLN CYS ASN GLU LEU LEU GLU ALA SEQRES 22 A 353 ASN PRO LYS ALA GLU GLY LEU LEU GLN GLY LYS HIS SER SEQRES 23 A 353 THR LYS GLY LEU GLY LYS MET ALA PRO SER SER ALA HIS SEQRES 24 A 353 PHE VAL THR LEU ASN GLY SER THR VAL PRO LEU GLY PRO SEQRES 25 A 353 ALA SER ASP THR GLY ILE LEU ASN PRO ASP GLY TYR THR SEQRES 26 A 353 LEU ASN TYR ASN GLU TYR ILE VAL TYR ASN PRO ASN GLN SEQRES 27 A 353 VAL ARG MET ARG TYR LEU LEU LYS VAL GLN PHE ASN PHE SEQRES 28 A 353 LEU GLN SEQRES 1 B 353 GLY PRO GLU SER GLN LEU ASP LEU ARG VAL GLN GLU LEU SEQRES 2 B 353 ILE LYS LEU ILE CYS ASN VAL GLN ALA MET GLU GLU MET SEQRES 3 B 353 MET MET GLU MET LYS TYR ASN THR LYS LYS ALA PRO LEU SEQRES 4 B 353 GLY LYS LEU THR VAL ALA GLN ILE LYS ALA GLY TYR GLN SEQRES 5 B 353 SER LEU LYS LYS ILE GLU ASP CYS ILE ARG ALA GLY GLN SEQRES 6 B 353 HIS GLY ARG ALA LEU MET GLU ALA CYS ASN GLU PHE TYR SEQRES 7 B 353 THR ARG ILE PRO HIS ASP PHE GLY LEU ARG THR PRO PRO SEQRES 8 B 353 LEU ILE ARG THR GLN LYS GLU LEU SER GLU LYS ILE GLN SEQRES 9 B 353 LEU LEU GLU ALA LEU GLY ASP ILE GLU ILE ALA ILE LYS SEQRES 10 B 353 LEU VAL LYS SER GLU ARG GLN GLY LEU GLU HIS PRO LEU SEQRES 11 B 353 ASP GLN HIS TYR ARG ASN LEU HIS CYS ALA LEU ARG PRO SEQRES 12 B 353 LEU ASP HIS GLU SER TYR GLU PHE LYS VAL ILE SER GLN SEQRES 13 B 353 TYR LEU GLN SER THR HIS ALA PRO THR HIS SER ASP TYR SEQRES 14 B 353 THR MET THR LEU LEU ASP LEU PHE GLU VAL GLU LYS ASP SEQRES 15 B 353 GLY GLU LYS GLU ALA PHE ARG GLU ASP LEU HIS ASN ARG SEQRES 16 B 353 MET LEU LEU TRP HIS GLY SER ARG MET SER ASN TRP VAL SEQRES 17 B 353 GLY ILE LEU SER HIS GLY LEU ARG ILE ALA PRO PRO GLU SEQRES 18 B 353 ALA PRO ILE THR GLY TYR MET PHE GLY LYS GLY ILE TYR SEQRES 19 B 353 PHE ALA ASP MET SER SER LYS SER ALA ASN TYR CYS PHE SEQRES 20 B 353 ALA SER ARG LEU LYS ASN THR GLY LEU LEU LEU LEU SER SEQRES 21 B 353 GLU VAL ALA LEU GLY GLN CYS ASN GLU LEU LEU GLU ALA SEQRES 22 B 353 ASN PRO LYS ALA GLU GLY LEU LEU GLN GLY LYS HIS SER SEQRES 23 B 353 THR LYS GLY LEU GLY LYS MET ALA PRO SER SER ALA HIS SEQRES 24 B 353 PHE VAL THR LEU ASN GLY SER THR VAL PRO LEU GLY PRO SEQRES 25 B 353 ALA SER ASP THR GLY ILE LEU ASN PRO ASP GLY TYR THR SEQRES 26 B 353 LEU ASN TYR ASN GLU TYR ILE VAL TYR ASN PRO ASN GLN SEQRES 27 B 353 VAL ARG MET ARG TYR LEU LEU LYS VAL GLN PHE ASN PHE SEQRES 28 B 353 LEU GLN HET ERV A 601 13 HET ERV B 601 13 HETNAM ERV 6-METHYLPYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE FORMUL 3 ERV 2(C8 H8 N4 O) HELIX 1 AA1 ASP A 235 CYS A 246 1 12 HELIX 2 AA2 ASN A 247 MET A 258 1 12 HELIX 3 AA3 PRO A 266 LEU A 270 5 5 HELIX 4 AA4 THR A 271 GLY A 292 1 22 HELIX 5 AA5 GLY A 295 ILE A 309 1 15 HELIX 6 AA6 THR A 323 SER A 349 1 27 HELIX 7 AA7 HIS A 356 HIS A 366 1 11 HELIX 8 AA8 SER A 376 THR A 389 1 14 HELIX 9 AA9 ARG A 431 SER A 433 5 3 HELIX 10 AB1 ASN A 434 GLY A 442 1 9 HELIX 11 AB2 PRO A 451 TYR A 455 5 5 HELIX 12 AB3 MET A 466 ASN A 472 1 7 HELIX 13 AB4 TYR A 473 PHE A 475 5 3 HELIX 14 AB5 ASN A 502 GLY A 507 5 6 HELIX 15 AB6 SER A 524 ALA A 526 5 3 HELIX 16 AB7 ASN A 563 ASN A 565 5 3 HELIX 17 AB8 ASP B 235 CYS B 246 1 12 HELIX 18 AB9 ASN B 247 GLU B 257 1 11 HELIX 19 AC1 THR B 271 GLY B 292 1 22 HELIX 20 AC2 ALA B 297 ILE B 309 1 13 HELIX 21 AC3 THR B 323 SER B 349 1 27 HELIX 22 AC4 HIS B 356 LEU B 365 1 10 HELIX 23 AC5 SER B 376 THR B 389 1 14 HELIX 24 AC6 ARG B 431 SER B 433 5 3 HELIX 25 AC7 ASN B 434 GLY B 442 1 9 HELIX 26 AC8 PRO B 451 TYR B 455 5 5 HELIX 27 AC9 MET B 466 ASN B 472 1 7 HELIX 28 AD1 TYR B 473 PHE B 475 5 3 HELIX 29 AD2 SER B 477 LYS B 480 5 4 HELIX 30 AD3 LYS B 504 LEU B 509 5 6 HELIX 31 AD4 ASN B 563 ASN B 565 5 3 SHEET 1 AA1 5 CYS A 367 PRO A 371 0 SHEET 2 AA1 5 TYR A 397 LYS A 409 -1 O GLU A 406 N ARG A 370 SHEET 3 AA1 5 VAL A 567 PHE A 579 -1 O ARG A 570 N VAL A 407 SHEET 4 AA1 5 THR A 482 VAL A 490 -1 N LEU A 487 O TYR A 571 SHEET 5 AA1 5 MET A 424 GLY A 429 -1 N MET A 424 O VAL A 490 SHEET 1 AA2 4 ILE A 461 PHE A 463 0 SHEET 2 AA2 4 GLU A 558 VAL A 561 -1 O TYR A 559 N PHE A 463 SHEET 3 AA2 4 SER A 514 GLY A 517 -1 N GLY A 517 O GLU A 558 SHEET 4 AA2 4 CYS A 495 LEU A 498 1 N ASN A 496 O LYS A 516 SHEET 1 AA3 2 PHE A 528 LEU A 531 0 SHEET 2 AA3 2 SER A 534 PRO A 537 -1 O VAL A 536 N VAL A 529 SHEET 1 AA4 5 CYS B 367 PRO B 371 0 SHEET 2 AA4 5 THR B 398 LYS B 409 -1 O GLU B 406 N ARG B 370 SHEET 3 AA4 5 VAL B 567 ASN B 578 -1 O ARG B 570 N VAL B 407 SHEET 4 AA4 5 THR B 482 ALA B 491 -1 N LEU B 487 O TYR B 571 SHEET 5 AA4 5 ARG B 423 GLY B 429 -1 N MET B 424 O VAL B 490 SHEET 1 AA5 3 ILE B 461 PHE B 463 0 SHEET 2 AA5 3 GLU B 558 VAL B 561 -1 O TYR B 559 N PHE B 463 SHEET 3 AA5 3 THR B 515 GLY B 517 -1 N GLY B 517 O GLU B 558 SHEET 1 AA6 2 MET B 521 ALA B 522 0 SHEET 2 AA6 2 SER B 542 ASP B 543 -1 O SER B 542 N ALA B 522 SHEET 1 AA7 2 VAL B 529 LEU B 531 0 SHEET 2 AA7 2 SER B 534 VAL B 536 -1 O VAL B 536 N VAL B 529 CRYST1 40.103 87.547 96.866 90.00 90.44 90.00 P 1 21 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.024936 0.000000 0.000191 0.00000 SCALE2 0.000000 0.011422 0.000000 0.00000 SCALE3 0.000000 0.000000 0.010324 0.00000